Perspectives on Adopting the Guideline for Multi-regional Clinical Trials in Korea: A Multi-stakeholder Survey
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Backgrounds: With the globalization of drug development, multi-regional clinical trials (MRCTs) have emerged to facilitate rapid availability of medicines to patients worldwide. The present study aimed to has explored attitudes and perceptions towards adopting the Korean MRCT guideline. Methods: An online survey, consisting of 16 questions, classified into two subjects, was administered to stakeholders in Korea. Most quantitative components were measured using the Likert scales. A content analysis of the qualitative components was carried out to identify the keywords in open-ended responses. Results: A total of 94 survey responses were analyzed: 51 participants from pharmaceutical companies, 11 from clinical research organizations, and 21 from clinical trial centers. The content of the guideline was rated as appropriate for clarity, acceptability, and applicability (96.8, 96.8, and 93.6%, respectively). The local environmental impact of the systemic/political, academic/technical, and industrial/economical aspects of the guideline was rated as appropriate at 95.7, 97.9, and 91.5%, respectively. The suggested adoption period was 1~2 years (40, 42.6%). The concept and individuals’ domestic circumstances were the key problems affecting the clarity, applicability, and local environmental impact of the guideline. Conclusion: The Korean MRCT guideline was well-developed. Their overall impact on the local environmental impact of MRCTs in Korea was expected to be beneficial, but methods are needed to minimize the negative impacts. The findings of this study can inform the priorities for the future adoption of the guideline in Korea.
Abstract
Backgrounds: With the globalization of drug development, multi-regional clinical trials (MRCTs) have emerged to facilitate rapid availability of medicines to patients worldwide. The present study aimed to has explored attitudes and perceptions towards adopting the Korean MRCT guideline. Methods: An online survey, consisting of 16 questions, classified into two subjects, was administered to stakeholders in Korea. Most quantitative components were measured using the Likert scales. A content analysis of the qualitative components was carried out to identify the keywords in open-ended responses. Results: A total of 94 survey responses were analyzed: 51 participants from pharmaceutical companies, 11 from clinical research organizations, and 21 from clinical trial centers. The content of the guideline was rated as appropriate for clarity, acceptability, and applicability (96.8, 96.8, and 93.6%, respectively). The local environmental impact of the systemic/political, academic/technical, and industrial/economical aspects of the guideline was rated as appropriate at 95.7, 97.9, and 91.5%, respectively. The suggested adoption period was 1~2 years (40, 42.6%). The concept and individuals’ domestic circumstances were the key problems affecting the clarity, applicability, and local environmental impact of the guideline. Conclusion: The Korean MRCT guideline was well-developed. Their overall impact on the local environmental impact of MRCTs in Korea was expected to be beneficial, but methods are needed to minimize the negative impacts. The findings of this study can inform the priorities for the future adoption of the guideline in Korea.
참고문헌 (40)
- "E17 General principles for planning and design of Multi-Regional Clinical Trials Draft" (2016)[URL]
- Weisfeld V, "International Regulatory Harmonization Amid Globalization of Drug Development", Workshop Summary of Forum on Drug Discovery, Development, and Translation, pp.5~9 (2013), Board on Health Sciences Policy; Institute of Medicine (IOM)
- Quan H, "Example-based illustrations of design, conduct, analysis and result interpretation of multi-regional clinical trials", Contemp Clin Trials, 58, pp.13~22 (2017)
- Shenoy P, "Multi-regional clinical trials and global drug development", Perspect Clin Res, 7, pp.62~67 (2016)
- Vickers A, "Do certain countries produce only positive results? A systematic review of controlled trials", Control Clin Trials, 19, pp.159~166 (1998)
- Okie S, "Multinational medicines—ensuring drug quality in an era of global manufacturing", N Engl J Med, 361, pp.737~740 (2009)
- Davis JR, "Assuring Data Quality and Validity in Clinical Trials for Regulatory Decision Making", Workshop Report of Institute of Medicine (US) Roundtable on Research and Development of Drugs, Biologics, and Medical Devices (1998)
- 송윤경, "다지역 임상시험의 계획 및 설계에 대한 국제 제도적 동향 분석", 한국임상약학회지, 28(2), pp.146~153 (2018), 한국임상약학회[DOI]
- "Basic principles on global clinical trials" (2007)[URL]
- "Basic Principles on Global Clinical Trials (Reference Cases)" (2012)[URL]
- "Basic Principles for Conducting Phase I Trials in the Japanese Population Prior to Global Clinical Trials" (2014)[URL]
- "International multicenter clinical trials Guidelines (Trial) Draft" (2014)[URL]
- "E17 General principles for planning and design of Multi-Regional Clinical Trials" (2017)[URL]
- "General principles for planning and design of Multi-Regional Clinical Trials" (2018)[URL]
- Dillman DA, "Internet, Mail and Mixed-Mode Surveys: The Tailored Design Method", pp.94~168 (2009), Wiley
- "Survey Sample Size Calculator"[URL]
- Brouwers MC, "AGREE II: advancing guideline development, reporting and evaluation in health care", CMAJ, 182, pp.E839~E842 (2010)
- Fervers B, "Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation", BMJ Qual Saf, 20, pp.228~236 (2011)
- Hsieh HF, "Three approaches to qualitative content analysis", Qual Health Res, 15, pp.1277~1288 (2005)
- Elo S, "The qualitative content analysis process", J Adv Nurs, 62, pp.107~115 (2008)
- Tavakol M, "Making sense of Cronbach's alpha", Int J Med Educ, 2, pp.53~55 (2011)
- Binkowitz B, "Multiregional Clinical Trials: An Introduction From an Industry Perspective", Drug Inf J, 45, pp.569~573 (2011)
- Singh J, "International conference on harmonization of technical requirements for registration of pharmaceuticals for human use", J Pharmacol Pharmacother, 6, pp.185~187 (2015)
- Siering U, "Appraisal tools for clinical practice guidelines: a systematic review", PLoS One, 8, pp.e82915~ (2013)
- MacDermid JC, "Reliability and validity of the AGREE instrument used by physical therapists in assessment of clinical practice guidelines", BMC Health Serv Res, 5, pp.18~ (2005)
- Hoffmann-Eßer W, "Guideline Appraisal With AGREE II: Systematic Review of the Current Evidence on How Users Handle the 2 Overall Assessments", PLoS One, 12, pp.e0174831~ (2017)
- Zhang X, "Clinical Practice Guidelines for Hypertension: Evaluation of Quality Using the AGREE II Instrument", Am J Cardiovasc Drugs, 16, pp.439~451 (2016)
- Yang C, "Quality assessment of clinical practice guidelines on tic disorders with AGREE II instrument", Psychiatry Res, 259, pp.385~391 (2018)
- "E5(R1) Ethnic Factors in the Acceptabilify of Foreign Clinical Data" (1998)[URL]
- Yi S, "Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment", Pharmacogenet Genomics, 24, pp.477~485 (2014)
- Hasunuma T, "Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians", Br J Clin Pharmacol, 81, pp.1078~1090 (2016)
- Gehring M, "Factors influencing clinical trial site selection in Europe: the Survey of Attitudes towards Trial sites in Europe (the SAT-EU Study)", BMJ Open, 3, pp.e002957~ (2013)
- Collier R, "Rapidly rising clinical trial costs worry researchers", CMAJ, 180, pp.277~278 (2009)
- "The right place for clinical tirals in Asia" (2017)[URL]
- Rajadhyaksha V, "Conducting feasibilities in clinical trials: an investment to ensure a good study", Perspect Clin Res, 1, pp.106~109 (2010)
- Chen J, "An adaptive strategy for assessing regional consistency in multiregional clinical trials", Clin Trials, 9, pp.330~339 (2012)
- Tsou HH, "Design and analysis issues of multiregional clinical trials with different regional primary endpoints", J Biopharm Stat, 22, pp.1051~1059 (2012)
- Chen YH, "Assessing dose-region profile of drug efficacy: a multiregional trial strategy", J Biopharm Stat, 22, pp.894~902 (2012)
- Hasson F, "Research guidelines for the Delphi survey technique", J Adv Nurs, 32, pp.1008~1015 (2000)
- Wong LP, "Focus group discussion: a tool for health and medical research", Singapore Med J, 49, pp.256~260 (2008)